ST. LOUIS – Centene Corporation (NYSE: NYSE:), a prominent healthcare enterprise, announced today that its subsidiary, Health Net Community Solutions, has been selected by the California Department of Health Care Services to provide managed dental health care services to Medi-Cal beneficiaries in Los Angeles and Sacramento counties starting July 1, 2025. The contract spans 54 months and marks the continuation of Health Net’s role as a provider of both medical and dental coverage in these regions.

Health Net, currently the sole Medi-Cal plan in the aforementioned counties that offers integrated medical and dental care, manages a network of over 1,000 dental providers. The company serves nearly 385,000 dental members and supports the health care needs of approximately 2.2 million Californians, including more than 1.5 million Medi-Cal members.

Centene CEO Sarah M. London expressed gratitude for the opportunity to support Medi-Cal members’ dental health needs through Health Net’s new contract. Health Net Plan President and CEO Brian Ternan also conveyed the organization’s commitment to improving community health and providing essential dental services.

The selection of Health Net is part of a broader strategy to address social determinants of health, aiming to reduce health disparities, enhance outcomes, and improve access to quality care. Health Net’s whole-person care model is designed to meet the comprehensive needs of its members.

Centene Corporation, a Fortune 500 company, focuses on serving under-insured and uninsured individuals through a variety of government-sponsored and commercial healthcare programs. The company’s approach emphasizes local brands and teams to deliver integrated, high-quality, and cost-effective services.

The information in this article is based on a press release statement.

In other recent news, Centene Corporation reported strong second-quarter earnings, with an adjusted diluted earnings per share (EPS) of $2.42, marking a 15% increase from the previous year. The company also raised its full-year premium and service revenue expectations to between $141 billion and $143 billion, indicating optimism about future growth.

In terms of analyst interactions, Jefferies maintained a Hold rating on Centene but lowered its price target to $72.00 from the previous $74.00, reflecting adjustments to the earnings forecasts for the next two years. Wells Fargo, on the other hand, upgraded its price target for Centene from $81.00 to $93.00, maintaining an Overweight rating on the stock. Similarly, TD Cowen increased Centene’s price target from $80.00 to $89.00, also reaffirming a Buy rating on the stock.

In other company news, Centene expanded its Board of Directors with the appointment of Thomas R. Greco, a seasoned leader with over 40 years of experience in public companies. This appointment is expected to enhance Centene’s consumer marketing expertise, aiding the company’s mission to improve the health of its members. These developments highlight Centene’s commitment to its growth strategy, focusing on improving Medicaid operations and marketplace innovation.

InvestingPro Insights

As Centene Corporation (NYSE: CNC) secures a new contract to provide managed dental health care services in California, the company’s financial health remains a key focus for investors. Centene’s aggressive share buyback program indicates strong confidence from management in the company’s value, which is an important consideration for shareholders.

Moreover, Centene’s position as a prominent player in the Healthcare Providers & Services industry is bolstered by its high shareholder yield, a metric that combines dividend payments and share repurchases to show the total payout to shareholders. Although Centene does not pay a dividend, the share repurchases contribute to this yield, rewarding investors and potentially signaling undervalued stock. With a market capitalization of $39.64 billion and a price-to-earnings (P/E) ratio of 14.26, the company is trading at a valuation that reflects its profitability over the last twelve months.

InvestingPro data provides additional context, showing that Centene is trading at a low revenue valuation multiple, with a price-to-book ratio in the last twelve months as of Q2 2024 at 1.45. This ratio suggests that the stock may be reasonably priced relative to the company’s book value. Additionally, Centene has demonstrated a revenue growth of 4.32% in the same period, showcasing its ability to increase earnings over time.

Investors interested in Centene’s future performance should note that 7 analysts have revised their earnings estimates downwards for the upcoming period, which could impact the stock’s near-term trajectory. Nonetheless, Centene’s fundamental strength is evident in its recent profitability and the expectation of analysts for the company to remain profitable this year.

For those seeking deeper financial analysis and more InvestingPro Tips, there are 11 additional tips available on Centene Corporation at https://www.investing.com/pro/CNC, providing valuable insights for making informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.